Skin Biopsy Devices Market By Product Type (Biopsy Punches, Shave-Biopsy Blades, Dermal Curettes, Scalpels and Excisional Instruments, Scissors and Snip-Biopsy Instruments, Biopsy Kits, Microbiopsy and Emerging Sampling Devices); By Usage (Disposable Devices, Reusable Instruments); By Application (Skin-Cancer Diagnosis, Atypical and Benign Lesion Assessment, Inflammatory Skin Disorders, Infectious Skin Diseases, Alopecia and Scalp Disorders, Neurological Biomarker Testing, Clinical Research and Molecular Analysis); By End User (Dermatology Clinics, Hospitals, Ambulatory and Outpatient Facilities, Diagnostic Laboratories, Academic and Clinical-Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Skin Biopsy Devices Market: Procedure-Led Demand Is Expanding Beyond Conventional Dermatology

The Global Skin Biopsy Devices Market was valued at USD 185 million in 2025 and is projected to reach USD 295 million by 2032, expanding at a CAGR of 6.9% during 2026–2032, according to Strategic Market Research.

 

Skin biopsy devices form a procedure-driven market for disposable instruments, minor Skin biopsy technologies have advanced considerably, shifting from conventional surgical excision toward minimally invasive microbiopsy and non-invasive tape-stripping techniques. Current solutions range from FDA-registered micro-tools designed for precise tissue sampling to advanced patch-based platforms. Emerging technologies also support genetic sequencing, molecular analysis, and targeted localised therapies. These innovations aim to improve diagnostic accuracy while reducing patient discomfort and recovery time.

 

Approximately 5.1 million skin biopsies are performed each year in the United States across healthcare providers. Tangential or shave biopsies represent 90.5% of all procedures, followed by punch biopsies at 8.7% and incisional biopsies at 0.8%. Skin biopsy utilization has historically increased by around 2% to 6% annually, supported by more frequent skin examinations and higher referral rates.

 

Medicare Procedure Volume Provides the Clearest U.S. Utilization Signal

CMS Medicare Physician and Other Practitioners by Geography and Service dataset identified 5,246,606 billed skin-biopsy services across CPT codes 11102–11107 in Original Medicare fee-for-service.

The total included 4,834,876 tangential-biopsy services, 374,880 punch-biopsy services, and 36,850 incisional-biopsy services. Tangential procedures represented approximately 92% of the combined volume, demonstrating the importance of shave blades, flexible cutting instruments, curettes, and other products used for superficial lesion sampling.

The CMS total covers Original Medicare Part B and represents billed services rather than unique patients. Several lesions may be sampled during one encounter, while one patient may return for repeat biopsies, lesion removal, or cancer surveillance. The data nevertheless confirms that skin biopsy is a recurring, high-volume outpatient procedure rather than a limited hospital intervention.

Procedure totals cannot be converted directly into physical device units because some biopsies use dedicated disposable punches or blades, while others use reusable scalpels, scissors, or curettes. Device consumption depends on product mix, procedure technique, reuse practices, and institutional purchasing policies.

 

Skin Cancer Remains the Largest Measurable Demand Base

Suspicious lesions and possible malignancies generate the strongest relationship between disease burden and device demand. Biopsy commonly provides histologic confirmation before excision, Mohs surgery, destruction, systemic treatment, or radiation is selected.

The American Cancer Society estimates that approximately 5.4 million basal and squamous cell skin-cancer cases occur annually among about 3.3 million people in the United States. The difference between cases and people reflects the frequency with which one patient develops multiple lesions, supporting repeat biopsy and instrument demand.

For melanoma, the American Cancer Society projects 112,000 new invasive cases and 8,510 deaths in the United States in 2026. A further 122,680 melanoma-in-situ diagnoses are projected, producing a combined pool of 234,680 invasive and in-situ diagnoses. These figures exclude the larger number of benign or atypical lesions biopsied to rule out melanoma.

IARC GLOBOCAN 2024 estimates include 337,969 new melanoma cases, 58,398 melanoma deaths, 1,138,314 new non-melanoma skin-cancer cases, and 58,721 non-melanoma skin-cancer deaths globally. Global non-melanoma incidence remains understated because basal cell carcinoma is excluded from the GLOBOCAN incidence category.

More than 40 million Americans also develop actinic keratoses annually. Most are assessed without biopsy, but sampling becomes more likely when lesions are thick, recurrent, changing, ulcerated, or clinically difficult to distinguish from squamous cell carcinoma.

 

Product Segmentation: Biopsy Punches Lead While Microbiopsy Gains Strategic Value

Biopsy Punches

Biopsy punches represented the largest product category with a 34.0% market share and USD 62.9 million in revenue in 2025. The segment is projected to reach USD 94.4 million by 2032, accounting for 32.0% of the market and expanding at a CAGR of 6.0%.

Punches are routinely used to obtain full-thickness cylindrical specimens in dermatology clinics, hospitals, and outpatient facilities. Standardized sizes, procedural familiarity, relatively low unit costs, and suitability for neoplastic, inflammatory, infectious, and scalp conditions support recurring demand.

Integra LifeSciences’ Miltex range includes sterile disposable biopsy punches, plunger-style punches, curettes, and biopsy blades. Acuderm supplies Acu-Punch products in multiple sizes, while KAI Industries maintains an international portfolio of biopsy punches and dermal curettes.

 

Shave-Biopsy Blades

Shave-biopsy blades accounted for 18.0% of the market and USD 33.3 million in 2025. The segment is projected to reach USD 50.2 million by 2032, representing 17.0% of market revenue and a CAGR of 6.0%.

Demand is concentrated in dermatology clinics and outpatient practices performing large numbers of superficial and raised-lesion assessments. The dominance of tangential procedures in Medicare service data supports the commercial importance of flexible shave blades, although procedure share does not translate directly into revenue share because prices and purchasing arrangements differ.

 

Dermal Curettes

Dermal curettes generated USD 22.2 million in 2025, equivalent to 12.0% of the market. Revenue is projected to reach USD 32.5 million by 2032, with market share easing to 11.0% and the segment expanding at a CAGR of 5.6%.

Curettes are used for superficial sampling, lesion removal, and selected combined diagnostic and therapeutic procedures. Their relative share is expected to decline modestly as standardized kits and emerging sampling products capture a larger portion of institutional purchasing budgets.

 

Scalpels and Excisional Instruments

Scalpels and excisional instruments accounted for 11.0% of the market and USD 20.4 million in 2025. The category is projected to reach USD 29.5 million by 2032, representing 10.0% of the market and a CAGR of 5.4%.

These instruments remain important when deeper tissue architecture, complete lesion removal, or margin assessment is required. Demand is concentrated in hospitals, surgical dermatology practices, and specialist clinics managing clinically suspicious or complex lesions.

 

Scissors and Snip-Biopsy Instruments

Scissors and snip-biopsy instruments held a 7.0% share valued at USD 13.0 million in 2025. Revenue is expected to reach USD 17.7 million by 2032, with share declining to 6.0% and a CAGR of 4.6%.

Their use is concentrated in narrower applications, including pedunculated lesions and tissue sampling from anatomically difficult sites. The limited procedure base results in slower growth than biopsy punches, kits, and microbiopsy devices.

 

Biopsy Kits

Biopsy kits represented 12.0% of the market and USD 22.2 million in 2025. The segment is projected to nearly double to USD 44.2 million by 2032, raising its share to 15.0% at a CAGR of 10.4%.

Kits consolidate instruments, specimen containers, dressings, anesthetic-delivery accessories, and other procedural components into standardized packages. Their adoption is supported by reduced preparation time, simpler inventory management, and consistent infection-control practices across clinicians and locations.

 

Microbiopsy and Emerging Sampling Devices

Microbiopsy and emerging sampling devices accounted for 6.0% of the market and USD 11.1 million in 2025. The category is projected to reach USD 26.6 million by 2032, increasing its share to 9.0% and registering the fastest product CAGR of 13.3%.

Growth is associated with demand for minimally invasive tissue collection, reduced scarring, repeated sampling, molecular profiling, biomarker assessment, and clinical research requiring smaller but analytically useful specimens.

 

Disposable Devices Strengthen Their Market Position

Disposable devices dominated the usage category with a 76.0% share and USD 140.6 million in revenue in 2025. The segment is projected to reach USD 236.0 million by 2032, increasing its share to 80.0% and expanding at a CAGR of 7.7%.

Single-use punches, blades, curettes, and kits support sterility, sharpness, contamination control, and procedural convenience. They also eliminate the operational burden associated with cleaning, sterilization, inspection, and instrument tracking.

Reusable instruments accounted for 24.0% and USD 44.4 million in 2025. Revenue is forecast to reach USD 59.0 million by 2032, although market share is expected to fall to 20.0% as the segment grows at a CAGR of 4.1%. Reusable scalpels, scissors, forceps, and selected excisional instruments remain relevant where facilities maintain established sterilization capacity and seek to control recurring consumable expenditure.

 

Skin-Cancer Diagnosis Accounts for More Than Half of Application Revenue

Skin-cancer diagnosis represented the largest application with a 52.0% share and USD 96.2 million in 2025. Revenue is projected to reach USD 162.2 million by 2032, increasing its share to 55.0% at a CAGR of 7.8%.

Demand is supported by suspicious-lesion assessment, greater awareness of melanoma and keratinocyte cancers, earlier dermatology referrals, and the need to distinguish malignant lesions from clinically similar benign conditions.

Atypical and benign lesion assessment generated USD 33.3 million in 2025, representing 18.0% of the market. The segment is projected to reach USD 50.2 million by 2032, with a 17.0% share and CAGR of 6.0%. It includes biopsies of atypical moles, keratoses, cysts, and other uncertain growths requiring pathological confirmation.

Inflammatory skin disorders accounted for 10.0% and USD 18.5 million in 2025. Revenue is expected to reach USD 26.6 million by 2032, representing 9.0% of the market and a CAGR of 5.3%. Biopsy is generally reserved for atypical or diagnostically uncertain inflammatory and autoimmune presentations.

Infectious skin diseases represented 6.0% and USD 11.1 million in 2025. The segment is projected to reach USD 16.2 million by 2032, with its share easing to 5.5% and a CAGR of 5.6%. Tissue sampling is most relevant in persistent, deep, unusual, treatment-resistant, or immunocompromised infections requiring pathology, staining, culture, or molecular testing.

Alopecia and scalp disorders accounted for 5.0% and USD 9.2 million in 2025. Revenue is projected to reach USD 13.3 million by 2032, representing 4.5% of the market and a CAGR of 5.3%. Punch biopsy remains important for differentiating scarring and non-scarring alopecia and evaluating complex inflammatory scalp conditions.

Neurological biomarker testing represented 3.0% of the market and USD 5.5 million in 2025. The segment is projected to reach USD 11.8 million by 2032, increasing its share to 4.0% and recording the fastest application CAGR of 11.4%.

CND Life Sciences’ Syn-One Test demonstrates this emerging pathway. The test uses three standard 3 mm punch-biopsy samples to detect abnormal phosphorylated alpha-synuclein in cutaneous nerves. A 2024 multicentre study involving 428 participants detected phosphorylated alpha-synuclein in 95.5% of participants with clinically confirmed synucleinopathies. The FDA granted the test Breakthrough Device designation in October 2025.

Clinical research and molecular analysis accounted for 6.0% and USD 11.1 million in 2025. The segment is projected to reach USD 14.8 million by 2032, representing 5.0% of the market and a CAGR of 4.1%. Its strategic importance exceeds its revenue share because it supports genomic, transcriptomic, proteomic, pharmacodynamic, and treatment-response studies.

 

Dermatology Clinics Remain the Primary Purchasing Centre

Dermatology clinics led the end-user market with a 44.0% share and USD 81.4 million in 2025. Revenue is projected to reach USD 135.7 million by 2032, increasing the segment’s share to 46.0% at a CAGR of 7.6%.

Clinics concentrate lesion evaluation, dermoscopic assessment, skin-cancer screening, biopsy procedures, and follow-up care. Their market position is strengthening as diagnostic and minor surgical procedures continue shifting toward specialized outpatient settings.

Hospitals accounted for 29.0% and USD 53.6 million in 2025. Revenue is forecast to reach USD 79.7 million by 2032, representing 27.0% of the market and a CAGR of 5.8%. Hospitals remain important for complex excisions, inpatient consultations, immunocompromised patients, unusual infections, and cases requiring multidisciplinary care.

Ambulatory and outpatient facilities generated USD 24.1 million in 2025, equivalent to 13.0% of the market. The segment is projected to reach USD 44.2 million by 2032, raising its share to 15.0% and producing the fastest end-user CAGR of 9.1%. Growth is supported by shorter appointment cycles, lower facility costs, and wider use of disposable biopsy kits.

Diagnostic laboratories represented 8.0% and USD 14.8 million in 2025. Revenue is projected to reach USD 20.7 million by 2032, with a 7.0% share and CAGR of 4.9%. Laboratories influence demand through specimen-quality requirements, molecular-testing protocols, pathology workflows, and supported collection programs.

Academic and clinical-research institutions accounted for 6.0% and USD 11.1 million in 2025. Revenue is expected to reach USD 14.8 million by 2032, representing 5.0% of the market and a CAGR of 4.1%. These institutions use skin-biopsy devices in biomarker discovery, dermatology trials, neurological research, and the evaluation of minimally invasive sampling methods.

 

Microbiopsy and Non-Invasive Technologies Are Redefining the Competitive Boundary

Trajan Scientific and Medical’s Harpera Microbiopsy Punch reflects the move toward smaller tissue samples for clinical research, biomarker analysis, and longitudinal monitoring. In July 2026, Trajan announced expanded U.S. availability following FDA registration for clinical skin sampling.

Harpera is positioned for settings where repeat sampling, reduced tissue disruption, and preservation of surrounding tissue are important. Early demand is likely to come from pharmaceutical studies, biomarker programs, specialist centres, and clinical research rather than immediate replacement of routine punch or shave biopsy.

DermTech’s melanoma assessment platform uses an adhesive Smart Sticker to collect material from the skin surface for gene-expression analysis. DermTech reports that more than 300,000 lesions have been tested and more than 4,300 clinicians have used its services.

Non-invasive genomic assessment may reduce conventional biopsies for lesions classified as low risk, while positive or inconclusive results can still lead to tissue sampling. These platforms therefore compete with part of the traditional biopsy pool while bringing more patients into structured lesion-assessment pathways.

Academic groups are also evaluating polymer and sodium-hyaluronate microneedle patches that collect immune cells, proteins, RNA, or interstitial fluid without removing a conventional tissue core. These technologies could eventually support repeated biomarker monitoring, decentralized sampling, and clinical-trial applications.

Therapeutic microneedle products remain outside the core biopsy-device market. Medicus Pharma’s SkinJect, for example, is designed to deliver doxorubicin into basal cell carcinoma lesions rather than acquire tissue for diagnosis.

 

Competition Spans Conventional Instruments and Diagnostic Platforms

The competitive field includes diversified surgical-instrument manufacturers, specialist dermatology suppliers, international distributors, and emerging molecular-diagnostic companies.

Relevant participants include Integra LifeSciences/Miltex, KAI Industries, Acuderm, AccuThrive/AccuTec, FEATHER Safety Razor, pfm medical, Robbins Instruments, Trajan Scientific and Medical, DermTech, and CND Life Sciences.

Traditional suppliers compete through sterile packaging, size availability, cutting consistency, distributor reach, purchasing contracts, and clinician familiarity. Emerging companies compete through clinical evidence, laboratory capabilities, reimbursement, specimen logistics, and access to specialist networks.

Purchasing power remains concentrated among dermatology practices, health systems, group purchasing organizations, and medical distributors. Independent clinics may favor familiar products and broad size availability, while larger systems typically standardize vendors and reduce the number of stocked product variants.

 

Asia-Pacific Becomes the Fastest-Growing Regional Market

North America held the largest regional share at 39.0%, valued at USD 72.2 million in 2025. The market is projected to reach USD 106.2 million by 2032, accounting for 36.0% of global revenue and expanding at a CAGR of 5.7%.

The region benefits from established dermatology infrastructure, substantial skin-cancer diagnostic activity, broad use of disposable instruments, and strong access to dermatopathology and molecular-testing services.

Europe accounted for 28.0% and USD 51.8 million in 2025. Revenue is projected to reach USD 79.7 million by 2032, representing 27.0% of the market and a CAGR of 6.3%. Demand is supported by established public and private dermatology services, organized cancer-diagnosis pathways, and consistent hospital and outpatient biopsy activity.

Asia-Pacific represented 24.0% and USD 44.4 million in 2025. The market is projected to reach USD 85.5 million by 2032, increasing its share to 29.0% and recording the fastest regional CAGR of 9.8%.

Expansion is supported by growing dermatology capacity, improving pathology access, rising diagnostic awareness, greater healthcare expenditure, and broader availability of affordable disposable instruments. Australia and New Zealand have high melanoma incidence, while Japan has an established manufacturing base through companies such as KAI and FEATHER.

Latin America accounted for 5.0% and USD 9.2 million in 2025. Revenue is projected to reach USD 13.3 million by 2032, representing 4.5% of the global market and a CAGR of 5.3%.

The Middle East and Africa represented 4.0% and USD 7.4 million in 2025. The region is expected to reach USD 10.3 million by 2032, accounting for 3.5% of the market and expanding at a CAGR of 4.9%. Growth remains concentrated in urban hospitals, specialist dermatology centres, and countries investing in pathology and cancer-diagnosis capacity.

 

Regulation Becomes More Important as Sampling Adds Molecular Claims

Conventional manual biopsy instruments are evaluated mainly through product classification, manufacturing controls, sterility, packaging, labelling, and intended use. Requirements become more complex when tissue collection is linked to genomic, protein, or other molecular analysis.

These platforms may involve medical-device oversight, clinical laboratory requirements, analytical validation, payer coverage, specimen logistics, and physician training. Commercial adoption increasingly depends on whether the result changes management, reduces unnecessary procedures, detects disease reliably, and fits existing pathology workflows.

 

Market Outlook: Value Is Shifting Toward the Information Obtained From Each Sample

The skin biopsy devices market will continue to rely on cancer-related lesion assessment, disposable biopsy punches and shave blades, outpatient procedure volume, and repeat purchasing by dermatology practices.

Biopsy punches will remain the largest product category, although kits and microbiopsy devices will gain share as healthcare facilities prioritize standardized preparation, sterility, repeat sampling, and molecular analysis. Disposable products will strengthen their dominance, while dermatology clinics and ambulatory facilities will capture a larger proportion of procedure activity.

Skin-cancer diagnosis will remain the principal application, but neurological biomarker testing and minimally invasive tissue sampling will broaden the market beyond conventional dermatology. Asia-Pacific will generate the strongest regional expansion as access to specialist care, pathology services, and disposable instruments improves.

Conventional suppliers will retain a high-volume consumables business built around punches, blades, curettes, scalpels, and kits. Emerging companies will compete through the diagnostic value attached to each sample, including the ability to support earlier diagnosis, reduce unnecessary excisions, enable repeat monitoring, and create new clinical testing pathways.

 

Skin Biopsy Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 185 Million
Revenue Forecast in 2032	USD 295 Million
Overall Growth Rate	CAGR of 6.9% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Usage, By Application, By End User, By Geography
By Product Type	Biopsy Punches, Shave-Biopsy Blades, Dermal Curettes, Scalpels and Excisional Instruments, Scissors and Snip-Biopsy Instruments, Biopsy Kits, Microbiopsy and Emerging Sampling Devices
By Usage	Disposable Devices, Reusable Instruments
By Application	Skin-Cancer Diagnosis, Atypical and Benign Lesion Assessment, Inflammatory Skin Disorders, Infectious Skin Diseases, Alopecia and Scalp Disorders, Neurological Biomarker Testing, Clinical Research and Molecular Analysis
By End User	Dermatology Clinics, Hospitals, Ambulatory and Outpatient Facilities, Diagnostic Laboratories, Academic and Clinical-Research Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising incidence of skin cancer and dermatological disorders, increasing demand for minimally invasive diagnostic procedures, growing adoption of disposable biopsy devices, and expansion of dermatology and pathology services
Customization Option	Available upon request